Protara Therapeutics

TARA · Nasdaq · United States

Share price · TARA

$2.34-1.64 (-41.21%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.1M (1.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when TARA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 11 Nov 2026+7.8%

    Nothing announced by TARA that day or the session before.

  2. 9 Nov 2026+9.1%
  3. 6 Nov 2026+8.0%
  4. 20 Oct 2026+9.9%

    Nothing announced by TARA that day or the session before.

  5. 15 Oct 2026-3.2%
  6. 14 Oct 2026-5.3%

    Nothing announced by TARA that day or the session before.

  7. 1 Oct 2026-9.5%

    Nothing announced by TARA that day or the session before.

  8. 30 Sep 2026-5.0%

    Nothing announced by TARA that day or the session before.

  9. 24 Sep 2026-5.4%

    Nothing announced by TARA that day or the session before.

  10. 1 Jul 2026+5.8%

    Nothing announced by TARA that day or the session before.

Share of unusual movement by asset

For each asset, the share of TARA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
TARA-002
events and moves
1212%
Other company news (earnings, financing, releases naming no asset)—41%
Sessions with no dated event—46%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Innate and adaptive immune activation (inactivated Streptococcus pyogenes)Bacterial immunotherapy
Bladder / Urothelial Cancer
Non-Muscle Invasive Bladder Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
TARA-002Phase 2Lymphatic Malformation
Est. primary completion 2026-12 · NCT05871970 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
TARA-002Phase 3Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma …
Est. primary completion 2028-04 · NCT07480356 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
TARA-002Phase 2Non-muscle Invasive Bladder Cancer
Est. primary completion 2031-10 · NCT05951179 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$17M$26M+ $102M short-term inv.$22M-$18M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$17M$18M+ $125M short-term inv.$22M-$15M operating cash flowreport ↗
2026-Q1—$14M$15M+ $121M short-term inv.$18M-$21M operating cash flowreport ↗
2025-Q3—$9.6M$13M+ $120M short-term inv.$13M-$12M operating cash flowreport ↗
2025-Q2—$11M$32M+ $91M short-term inv.$15M-$12M operating cash flowreport ↗
2025-Q1—$9.2M$92M+ $33M short-term inv.$12M-$15M operating cash flowreport ↗
2024-Q3—$8.1M$53M+ $30M short-term inv.$11M-$8.4M operating cash flowreport ↗
2024-Q2—$6.4M$90M$9.5M-$7.7M operating cash flowreport ↗
2024-Q1—$7.8M$53M+ $3.0M short-term inv.$11M-$10M operating cash flowreport ↗
2023-Q3—$6.2M$35M+ $40M short-term inv.$9.9M-$6.6M operating cash flowreport ↗
2023-Q2—$7.3M$35M+ $46M short-term inv.$11M-$9.4M operating cash flowreport ↗
2023-Q1—$5.1M$22M+ $66M short-term inv.$9.1M-$13M operating cash flowreport ↗
2022-Q3—$3.5M$48M+ $49M short-term inv.$7.7M-$5.3M operating cash flowreport ↗
2022-Q2—$3.1M$35M+ $65M short-term inv.$8.5M-$5.1M operating cash flowreport ↗
2022-Q1—$5.3M$26M+ $62M short-term inv.$11M-$11M operating cash flowreport ↗
2021-Q3—$4.1M$41M+ $53M short-term inv.$11M-$6.2M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$43M$50M+ $106M short-term inv.$14M-$56M operating cash flowreport ↗

Protara did not disclose revenue for 2025. Full-year R&D expense was $42.6M, up 34.5% YoY from $31.7M, and the company reported a net loss of $57.4M, or $1.34 per share. Cash, cash equivalents and marketable debt securities totaled $197.9M as of December 31, 2025, including proceeds from an $86.3M public offering, and the company expects this to fund planned operations into 2028.

Clinically, Protara reported ADVANCED-2 interim data in non-muscle invasive bladder cancer showing a 68% complete response rate at six months in BCG-unresponsive patients, and it received Breakthrough Therapy and Fast Track designations for TARA-002 in lymphatic malformations. The company expects to complete enrollment of the BCG-unresponsive registrational cohort and initiate the ADVANCED-3 registrational trial in 2H 2026, with a regulatory update for lymphatic malformations expected in 1H 2026 and THRIVE-3 interim results expected in 2H 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$32M$164M+ $7.5M short-term inv.$11M-$36M operating cash flowreport ↗
2023-FY—$25M$40M+ $26M short-term inv.$10M-$38M operating cash flowreport ↗
2022-FY—$17M$25M+ $60M short-term inv.$16M-$26M operating cash flowreport ↗
2021-FY—$21M$36M+ $56M short-term inv.$12M-$35M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 3 sales ($1.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-30Shefferman Jesse · director, CEO and PresidentGift14,000——Form 4
2026-06-30Shefferman Jesse · director, CEO and PresidentGift7,000——Form 4
2026-06-30Shefferman Jesse · director, CEO and PresidentGift4,000——Form 4
2026-06-30Shefferman Jesse · director, CEO and PresidentGift5,000——Form 4
2026-06-29Shefferman Jesse · director, CEO and PresidentOption exercise215,687$1.91$412KForm 4
2026-06-29Shefferman Jesse · director, CEO and PresidentOpen-market sale215,687$4.09$882KForm 4
2026-06-29Shefferman Jesse · director, CEO and PresidentOption exercise (derivative)215,687——Form 4
2026-06-15BESHAR LUKE M · directorAward / grant (derivative)31,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 113 reporting institutions held 45.6M shares ($237.1M, 81.1% of shares outstanding).

#InstitutionSharesValue
1JANUS HENDERSON GROUP PLC5,207,011$27.2M
2BlackRock, Inc.3,394,968$17.7M
3Velan Capital Investment Management LP2,834,652$14.8M
4MILLENNIUM MANAGEMENT LLC2,831,208$14.8M
5Blackstone Inc.2,265,514$11.8M
6VANGUARD CAPITAL MANAGEMENT LLC2,119,018$11.0M
7Sio Capital Management, LLC1,969,839$10.3M
8ACORN CAPITAL ADVISORS, LLC1,752,115$9.1M
9Integral Health Asset Management, LLC1,750,000$9.1M
10AIGH Capital Management LLC1,622,733$8.5M
11UBS Group AG1,402,413$7.3M
125AM Venture Management, LLC1,369,782$7.1M
13GEODE CAPITAL MANAGEMENT, LLC1,177,200$6.1M
14Point72 Asset Management, L.P.1,152,714$6.0M
15CITADEL ADVISORS LLC1,068,558$5.6M